Article Information
History
- September 6, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Stefan Halbherr1,
- Stefanie Lerch1,2,
- Sebastian Bellwald3,
- Petra Polakova1,4,
- Bettina Bannert5,
- Marie Roumet6,
- Roch-Philippe Charles1,7,
- Martin A. Walter8,
- Corrado Bernasconi9,
- Camille Peitsch1,
- Pascal C. Baumgartner1,
- Céline Kaufmann1,
- Heinrich P. Mattle10,
- Alain Kaelin-Lang11,
- Andreas Hartmann12 and
- Michael Schuepbach3,*
- 1InnoMedica Schweiz AG, Switzerland
- 2Skin and Soft Tissue Research Center, University Children’s Hospital Zurich, Switzerland
- 3Institute of Neurology, Konolfingen, Switzerland
- 4Swiss pediatric oncology group, Bern, Switzerland
- 5Department of Clinical Research, University of Basel, Switzerland
- 6Department of Clinical Research, University of Bern, Switzerland
- 7Swiss Group for Clinical Cancer Research, Switzerland
- 8St. Anna Hospital, University of Lucerne, Switzerland
- 9Limites Medical Research Ltd., Vacallo, Switzerland
- 10University of Bern, Switzerland
- 11Ente Ospedaliero Cantonale, Lugano Switzerland
- 12Assistance-Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Neurologie, Paris, France
- ↵*corresponding Author E-mail: nik{at}hin.ch
Posted September 06, 2024.
Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single center open-label clinical phase I trial (NEON trial)
